Of importance, emerging evidence have shown that YAP is overexpressed and contributes to acquired resistance and poor prognosis of cetuximab in HNSCC or EGFR TKIs in lung cancers52–56. The gene discussed is YAP1; the disease is head and neck squamous cell carcinoma.